Among patients with muscle-invasive bladder cancer, dose-dense MVAC significantly improved the 3-year rate of PFS and time to progression vs gemcitabine plus cisplatin in the neoadjuvant setting.
In a head-to-head trial in patients with previously treated HER2-positive metastatic breast cancer, trastuzumab deruxtecan reduced risk of disease progression or death by 72% compared with trastuzumab emtansine, a current standard of care.
In this combined analysis from the ongoing STAMPEDE platform trial, 2 years of abiraterone acetate plus prednisolone added to ADT was associated with a significant improvement in metastasis-free survival and OS in patients with high-risk nonmetastatic prostate cancer.
In this randomized, phase III trial, the addition of abiraterone to ADT plus docetaxel was associated with a significant improvement in rPFS and overall survival in men with de novo metastatic CSPC.
With additional follow-up, nivolumab + CT continued to show an OS benefit over CT alone in previously untreated patients with advanced gastroesophageal cancers.
[vic]-Trastuzumab duocarmazine, a novel antibody–drug conjugate, improved median PFS vs physician’s choice therapy in pretreated HER2+ locally advanced or metastatic breast cancer.
Addition of pembrolizumab to chemotherapy improved both OS and PFS in patients with locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 CPS ≥10.
In patients with colorectal cancer and unresectable liver metastases, the addition of transarterial radioembolization with yttrium-90 to second-line chemotherapy demonstrated significant improvements in PFS and hepatic PFS with a higher rate of grade ≥3 toxicity.
Phase Ib results suggest cabozantinib plus atezolizumab may be active in mCRPC patients with visceral or extrapelvic lymph node metastases.
In this single-arm study in patients with previously treated HER2-mutated NSCLC, trastuzumab deruxtecan demonstrated robust antitumor activity with a safety profile consistent with previous reports.
In this phase I study subset analysis, datopotamab deruxtecan demonstrated antitumor activity and manageable toxicity in patients with heavily pretreated advanced NSCLC with actionable genomic alterations.
In this single-arm phase II trial, second-line therapy with trastuzumab deruxtecan showed a response rate of 38% and durable responses following a trastuzumab-containing regimen in Western patients with HER2+ advanced gastric or GEJ cancer with no unexpected adverse events.
After a median follow-up of more than 3 years, this update showed sustained overall survival benefit with adding durvalumab to etoposide/platinum chemotherapy for the first-line treatment of patients with extensive-stage SCLC.
In this final analysis of the landmark COSMIC-311 trial, cabozantinib maintained a significant PFS benefit vs placebo in patients with radioiodine-refractory/-ineligible differentiated thyroid cancer after prior VEGFR TKI therapy.
In patients with previously treated mCRPC, the addition of 177Lu-PSMA-617 to standard of care resulted in improvements in health-related quality of life and time to worsening of pain and first symptomatic skeletal events, in addition to the previously reported OS and rPFS benefits.